Table 2.
Opportunistic Infections Observed During Ibrutinib Treatment
| Type of infection | No. (%) total = 23 | Location(s) | Alivea |
|---|---|---|---|
| Fungal | 17 (74) | ||
| Aspergillosisb | 12 | Lung (10), Brain (1), Lung/Hepatic (1) | Y (5), N (7) |
| Mucormycosisc | 2 | Sinuses (1), Brain (1) | Y (2) |
| Cryptococcosis | 1 | Disseminated (1) | Y (1) |
| Blastomycosis | 1 | Disseminated (1) | N (1) |
| Histoplasmosis | 1 | Disseminated (1) | Y (1) |
| Bacterial | 2 (7) | ||
| MAC | 2 | Lung (2) | Y (1), N (1) |
| Viral | 3 (13) | ||
| JC Virus (PML) | 2 | Brain (2) | N (2) |
| BK Virus | 1 | Urinary (1) | Y (1) |
| Parasite | 1 (4) | ||
| Toxoplasmosis | 1 | Chorioretinitis (1) | Y (1) |
a
At last follow-up
b
Probable pulmonary aspergillosis (n=9), proven aspergillosis (n=3)
c
Both proven mucomycosis
MAC = Mycobacterium Avium Complex, PML = Progressive multifocal leukoencephalopathy